Chemotherapy Before Surgery for Borderline Resectable Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of pancreatic cancer that is borderline resectable (meaning it may be removable with surgery after some chemotherapy)
- You are in generally good health (able to care for yourself)
- Your blood counts and organ function (liver, kidneys) are within a healthy range
- You have not had chemotherapy or radiation for this cancer before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
This study tests whether tailoring chemotherapy drugs to your tumor's genetic signature helps treat borderline resectable pancreatic cancer (a type that sits between operable and inoperable). You'll receive chemotherapy before surgery, and the combination used will depend on specific markers found in your tumor.
This trial tests whether a special MRI scan can help doctors better plan treatment for people with pancreatic cancer that is borderline able to be removed by surgery. The study will check how the tumor responds to initial treatment before surgery.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests a combination of chemotherapy drugs (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with pancreatic cancer that is on the border of being removable. The goal is to see if this treatment helps shrink the tumor and improve outcomes.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.